Cost‐effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population
Open Access
Abstract
BACKGROUND: Previous cost‐effectiveness analyses of tamoxifen therapy account for breast cancer risk reduction during active treatment but not for its persistent protective effect after active treatment.METHODS: A detailed, continuous time, mathematical model of breast cancer and healthcare processes was used to simulate a postmenopausal population aged cost saving when higher risk populations were targeted (5‐year risk ≥1.66%). The cost‐effectiveness results were sensitive to parameters that characterized menopausal symptoms and adverse side effects of tamoxifen.CONCLUSIONS: The current results indicated that tamoxifen chemoprophylaxis for postmenopausal women aged <55 years is a cost‐effective health policy that reduces breast cancer incidence and improves life expectancy. Focusing on a postmenopausal population aged <55 years minimized the threat of adverse events associated with tamoxifen. Cancer 2011. © 2011 American Cancer Society.Keywords
This publication has 50 references indexed in Scilit:
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast CancerCancer Prevention Research, 2010
- Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in JapanBritish Journal of Cancer, 2009
- Tamoxifen for Breast Cancer Risk ReductionMedical Care, 2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With HysterectomyJNCI: Journal of the National Cancer Institute, 2007
- Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trialBreast Cancer Research and Treatment, 2007
- Decision-Making About Tamoxifen in Women at High Risk for Breast Cancer: Clinical and Psychological FactorsJournal of Clinical Oncology, 2004
- The American Cancer Society Cancer Prevention Study II Nutrition CohortCancer, 2002
- Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary PreventionAnnals of Surgical Oncology, 2001
- Epidemiology of Recurrent Cerebral InfarctionStroke, 1999